Search

Your search keyword '"Ghia A"' showing total 371 results

Search Constraints

Start Over You searched for: Author "Ghia A" Remove constraint Author: "Ghia A" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
371 results on '"Ghia A"'

Search Results

5. Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia

9. Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression

10. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib

14. Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

15. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in patients with CLL

16. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

18. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

19. Genetic and phenotypic attributes of splenic marginal zone lymphoma

23. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL

27. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

31. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

33. MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

36. CLL-137 SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib Versus Bendamustine + Rituximab (BR) in Patients With Treatment-Naïve (TN) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/ SLL)

37. CLL-120 Pirtobrutinib, A Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated CLL/SLL: Updated Results from the Phase 1/2 BRUIN Study

38. CLL-114 BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

46. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

48. HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment

49. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations

50. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

Catalog

Books, media, physical & digital resources